Chwilio Deddfwriaeth

Chwiliad Uwch

Council Regulation (EEC) No 2377/90 (repealed)Dangos y teitl llawn

Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (repealed)

Help about what version

Pa Fersiwn

Rhagor o Adnoddau

PDF o Fersiynau Diwygiedig

Help about UK-EU Regulation

Legislation originating from the EU

When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.

Close

Mae hon yn eitem o ddeddfwriaeth sy’n deillio o’r UE

Mae unrhyw newidiadau sydd wedi cael eu gwneud yn barod gan y tîm yn ymddangos yn y cynnwys a chyfeirir atynt gydag anodiadau.Ar ôl y diwrnod ymadael bydd tair fersiwn o’r ddeddfwriaeth yma i’w gwirio at ddibenion gwahanol. Y fersiwn legislation.gov.uk yw’r fersiwn sy’n weithredol yn y Deyrnas Unedig. Y Fersiwn UE sydd ar EUR-lex ar hyn o bryd yw’r fersiwn sy’n weithredol yn yr UE h.y. efallai y bydd arnoch angen y fersiwn hon os byddwch yn gweithredu busnes yn yr UE. EUR-Lex Y fersiwn yn yr archif ar y we yw’r fersiwn swyddogol o’r ddeddfwriaeth fel yr oedd ar y diwrnod ymadael cyn cael ei chyhoeddi ar legislation.gov.uk ac unrhyw newidiadau ac effeithiau a weithredwyd yn y Deyrnas Unedig wedyn. Mae’r archif ar y we hefyd yn cynnwys cyfraith achos a ffurfiau mewn ieithoedd eraill o EUR-Lex. The EU Exit Web Archive legislation_originated_from_EU_p3

Changes to legislation:

This version of this Regulation was derived from EUR-Lex on IP completion day (31 December 2020 11:00 p.m.). It has not been amended by the UK since then. Find out more about legislation originating from the EU as published on legislation.gov.uk. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

Information:

You searched for provisions that are applicable to Scotland. The matching provisions are highlighted below. Where no highlighting is shown the matching result may be contained within a footnote.

  1. Introductory TextNext Match

  2. Article 1.. . . . . . . . . ....Previous MatchNext Match

  3. Article 2.. . . . . . . . . ....Previous MatchNext Match

  4. Article 3.. . . . . . . . . ....Previous MatchNext Match

  5. Article 4.. . . . . . . . . ....Previous MatchNext Match

  6. Article 5.. . . . . . . . . ....Previous MatchNext Match

  7. Article 6.. . . . . . . . . ....Previous MatchNext Match

  8. Article 7.. . . . . . . . . ....Previous MatchNext Match

  9. Article 8.. . . . . . . . . ....Previous MatchNext Match

  10. Article 9.. . . . . . . . . ....Previous MatchNext Match

  11. Article 10.. . . . . . . . . ....Previous MatchNext Match

  12. Article 11.. . . . . . . . . ....Previous MatchNext Match

  13. Article 12.. . . . . . . . . ....Previous MatchNext Match

  14. Article 13.. . . . . . . . . ....Previous MatchNext Match

  15. Article 14.. . . . . . . . . ....Previous MatchNext Match

  16. Article 15.. . . . . . . . . ....Previous MatchNext Match

  17. Article 16.. . . . . . . . . ....Previous MatchNext Match

  18. SignaturePrevious MatchNext Match

    1. ANNEX IPrevious MatchNext Match

      LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES FOR WHICH MAXIMUM RESIDUE LIMITS HAVE BEEN FIXEDPrevious MatchNext Match

      1. 1. Anti-infectious agents Previous MatchNext Match

        1. 1.1. Chemotheurapeutics Previous MatchNext Match

          1. 1.1.1. Sulfonamides Previous MatchNext Match

          2. 1.1.2. Diamino pyrimidine derivatives Previous MatchNext Match

        2. 1.2. Antibiotics Previous MatchNext Match

          1. 1.2.1. Penicillins Previous MatchNext Match

          2. 1.2.2. Cephalosporins Previous MatchNext Match

          3. 1.2.3. Quinolones Previous MatchNext Match

          4. 1.2.4. Macrolides Previous MatchNext Match

          5. 1.2.5. Florfenicol and related compounds Previous MatchNext Match

          6. 1.2.6. Tetracyclines Previous MatchNext Match

          7. 1.2.7. Naphtalene-ringed ansamycin Previous MatchNext Match

          8. 1.2.8. Pleuromutilines Previous MatchNext Match

          9. 1.2.9. Lincosamides Previous MatchNext Match

          10. 1.2.10. Aminoglycosides Previous MatchNext Match

          11. 1.2.11. Other antibiotics Previous MatchNext Match

          12. 1.2.12. Polypeptides Previous MatchNext Match

          13. 1.2.13. Beta-lactamase inhibitors Previous MatchNext Match

          14. 1.2.14. Polymyxins Previous MatchNext Match

          15. 1.2.15. Orthosomycins Previous MatchNext Match

          16. 1.2.16. Ionophores Previous MatchNext Match

      2. 2. Antiparasitic agents Previous MatchNext Match

        1. 2.1. Agents acting against endoparasites Previous MatchNext Match

          1. 2.1.1. Salicylanilides Previous MatchNext Match

          2. 2.1.2. Tatra-hydro-imidazoles (imidazolthiazoles) Previous MatchNext Match

          3. 2.1.3. Benzimidazoles and pro-benzimidazoles Previous MatchNext Match

          4. 2.1.4. Phenol derivatives including salicylanides Previous MatchNext Match

          5. 2.1.5. Benzenesulphonamides Previous MatchNext Match

          6. 2.1.6. Piperazine derivatives Previous MatchNext Match

          7. 2.1.7. Tetrahydropyrimides Previous MatchNext Match

          8. 2.1.8. Others Previous MatchNext Match

        2. 2.2. Agents acting against ectoparasites Previous MatchNext Match

          1. 2.2.1. Organophosphates Previous MatchNext Match

          2. 2.2.2. Formamidines Previous MatchNext Match

          3. 2.2.3. Pyrethroids Previous MatchNext Match

          4. 2.2.4. Acyl urea derivatives Previous MatchNext Match

          5. 2.2.5. Pyrimidines derivatives Previous MatchNext Match

          6. 2.2.6. Triazine derivatives Previous MatchNext Match

        3. 2.3. Agents acting against endo- and ectoparasites Previous MatchNext Match

          1. 2.3.1. Avermectins Previous MatchNext Match

        4. 2.4. Agents acting against protozoa Previous MatchNext Match

          1. 2.4.1. Triazinetrione derivative Previous MatchNext Match

          2. 2.4.2. Quinazolone derivatives Previous MatchNext Match

          3. 2.4.3. Carbanilides Previous MatchNext Match

          4. 2.4.4. Ionophores Previous MatchNext Match

      3. 3. Agents acting on the nervous system Previous MatchNext Match

        1. 3.1. Agents acting on the central nervous system Previous MatchNext Match

          1. 3.1.1. Butyrophenone tranquillisers Previous MatchNext Match

        2. 3.2. Agents acting on the autonomic nervous system Previous MatchNext Match

          1. 3.2.1. Anti-adrenergics Previous MatchNext Match

          2. 3.2.2. β2 sympathomimetic agents Previous MatchNext Match

      4. 4. Anti-inflammatory agents Previous MatchNext Match

        1. 4.1. Nonsteroidal anti-inflammatory agents Previous MatchNext Match

          1. 4.1.1. Arylpropionic acid derivative Previous MatchNext Match

          2. 4.1.2. Fenamate group derivatives Previous MatchNext Match

          3. 4.1.3. Enolic acid derivates Previous MatchNext Match

          4. 4.1.4. Oxican derivatives Previous MatchNext Match

          5. 4.1.5. Pyrazolone derivatives Previous MatchNext Match

          6. 4.1.6. Phenyl acetic acid derivatives Previous MatchNext Match

          7. 4.1.7. Sulphonated fenyl lactones Previous MatchNext Match

      5. 5. Corticoides Previous MatchNext Match

        1. 5.1. Glucocorticoides Previous MatchNext Match

      6. 6. Agents acting on the reproductive system Previous MatchNext Match

        1. 6.1. Progestogens Previous MatchNext Match

    2. ANNEX IIPrevious MatchNext Match

      LIST OF SUBSTANCES NOT SUBJECT TO MAXIMUM RESIDUE LIMITSPrevious MatchNext Match

      1. 1. Inorganic chemicals Previous MatchNext Match

      2. 2. Organic compounds Previous MatchNext Match

      3. 3. Substances generally recognised as safe Previous MatchNext Match

      4. 4. Substances used in homeopathic veterinary medicinal products Previous MatchNext Match

      5. 5. Substances used as food additives in foodstuffs for human consumption...Previous MatchNext Match

      6. 6. Substances of vegetable origin Previous MatchNext Match

      7. 7. Anti-infectious agents Previous MatchNext Match

      8. 8. Anti-inflammatory agents Previous MatchNext Match

    3. ANNEX IIIPrevious MatchNext Match

      LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES USED IN VETERINARY MEDICINAL PRODUCTS FOR WHICH PROVISIONAL MAXIMUM RESIDUE LIMITS HAVE BEEN FIXEDPrevious MatchNext Match

      1. 1. Anti-infectious agents Previous MatchNext Match

        1. 1.1. Chemotheurapeutics Previous MatchNext Match

          1. 1.1.2. Benzenesulphonamides Previous MatchNext Match

        2. 1.2. Antibiotics Previous MatchNext Match

          1. 1.2.1. Beta-lactamase inhibitors Previous MatchNext Match

          2. 1.2.2. Macrolides Previous MatchNext Match

          3. 1.2.4. Cephalosporins Previous MatchNext Match

          4. 1.2.5. Aminoglycosides Previous MatchNext Match

          5. 1.2.6. Quinolones Previous MatchNext Match

          6. 1.2.9. Polymyxins Previous MatchNext Match

          7. 1.2.10. Penicillins Previous MatchNext Match

          8. 1.2.11. Florfenicol and related compounds Previous MatchNext Match

          9. 1.2.12. Polypeptides Previous MatchNext Match

          10. 1.2.13. Lincosamides Previous MatchNext Match

          11. 1.2.14. Pleuromutilines Previous MatchNext Match

      2. 2. Antiparasitic agents Previous MatchNext Match

        1. 2.1. Agents acting against endoparasites Previous MatchNext Match

          1. 2.1.1. Phenol derivatives including salicylanides Previous MatchNext Match

          2. 2.1.2. Benzimidazoles and pro-benzimidazoles Previous MatchNext Match

          3. 2.1.3. Tetrahydropyrimides Previous MatchNext Match

          4. 2.1.5. Piperazine derivatives Previous MatchNext Match

          5. 2.1.6. Salicylanilides Previous MatchNext Match

          6. 2.1.8. Others Previous MatchNext Match

        2. 2.2. Agents acting against ectoparasites Previous MatchNext Match

          1. 2.2.1. Formamidines Previous MatchNext Match

          2. 2.2.2. Iminophenyl thiazolidine derivative Previous MatchNext Match

          3. 2.2.3. Pyretrin and pyrethroids Previous MatchNext Match

          4. 2.2.4. Organophosphates Previous MatchNext Match

          5. 2.2.5. Acyl urea derivates Previous MatchNext Match

          6. 2.2.6. Pyrimidines derivatives Previous MatchNext Match

          7. 2.2.7. Triazine derivatives Previous MatchNext Match

        3. 2.3. Agents acting against endo- and ectoparasites Previous MatchNext Match

          1. 2.3.1. Avermectins Previous MatchNext Match

        4. 2.4. Agents acting against protozoa Previous MatchNext Match

          1. 2.4.1. Carbanilides Previous MatchNext Match

          2. 2.4.2. Quinazolone derivatives Previous MatchNext Match

          3. 2.4.3. Triazinetrione derivatives Previous MatchNext Match

          4. 2.4.4. Other anti-protozoal agents Previous MatchNext Match

          5. 2.4.5. Ionophores Previous MatchNext Match

      3. 3. Agents acting on the nervous system Previous MatchNext Match

        1. 3.2. Agents acting on the autonomic nervous system Previous MatchNext Match

          1. 3.2.1. β 2 sympathomimetic agents Previous MatchNext Match

          2. 3.2.2. Anti-adrenergics Previous MatchNext Match

      4. 5. Anti-inflammatory agents Previous MatchNext Match

        1. 5.1. Nonsteroidal anti-inflammatory agents Previous MatchNext Match

          1. 5.1.1. Arylpropionic acid derivative Previous MatchNext Match

          2. 5.1.2. Enolic acid derivates Previous MatchNext Match

          3. 5.1.3. Pyrazolone derivatives Previous MatchNext Match

          4. 5.1.4. Sulfonated phenyl lactones Previous MatchNext Match

      5. 6. Agents acting on the reproductive system Previous MatchNext Match

        1. 6.1. Progestogens Previous MatchNext Match

      6. 7. Corticoids Previous MatchNext Match

        1. 7.1. Glucocorticoids Previous MatchNext Match

    4. ANNEX IVPrevious MatchNext Match

      LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES FOR WHICH NO MAXIMUM LEVELS CAN BE FIXEDPrevious MatchNext Match

      1. . . . . . . . . . ....Previous MatchNext Match

    5. ANNEX VPrevious MatchNext Match

      Information and particulars to be included in an application for the establishment of a maximum residue limit for a pharmacologically active substance used in veterinary medicinal productsPrevious MatchNext Match

      1. Administrative particulars Previous MatchNext Match

        1. 1 . . . . . . . . . ....Previous MatchNext Match

        2. 2 . . . . . . . . . ....Previous MatchNext Match

        3. 3 . . . . . . . . . ....Previous MatchNext Match

        4. 4 . . . . . . . . . ....Previous MatchNext Match

        5. 5 . . . . . . . . . ....Previous MatchNext Match

        6. 6 . . . . . . . . . ....Previous MatchNext Match

        7. A. Safety documentation Previous MatchNext Match

          1. A.0. . . . . . . . . . ....Previous MatchNext Match

          2. A.1. Precise identification of the substance concerned by the application Previous MatchNext Match

            1. 1.1 . . . . . . . . . ....Previous MatchNext Match

            2. 1.2 . . . . . . . . . ....Previous MatchNext Match

            3. 1.3 . . . . . . . . . ....Previous MatchNext Match

            4. 1.4 Classification: Previous MatchNext Match

            5. 1.5 . . . . . . . . . ....Previous MatchNext Match

            6. 1.6 . . . . . . . . . ....Previous MatchNext Match

            7. 1.7 . . . . . . . . . ....Previous MatchNext Match

            8. 1.8 . . . . . . . . . ....Previous MatchNext Match

            9. 1.9 . . . . . . . . . ....Previous MatchNext Match

            10. 1.10 . . . . . . . . . ....Previous MatchNext Match

            11. 1.11 Description of physical properties: Previous MatchNext Match

          3. A.2. Relevant pharmacological studies Previous MatchNext Match

            1. 2.1 . . . . . . . . . ....Previous MatchNext Match

            2. 2.2 . . . . . . . . . ....Previous MatchNext Match

          4. A.3. Toxicological studies Previous MatchNext Match

            1. 3.1 . . . . . . . . . ....Previous MatchNext Match

            2. 3.2 . . . . . . . . . ....Previous MatchNext Match

            3. 3.3 . . . . . . . . . ....Previous MatchNext Match

            4. 3.4 Reproductive toxicity, including teratogenicity. Previous MatchNext Match

              1. 3.4.1 . . . . . . . . . ....Previous MatchNext Match

              2. 3.4.2 . . . . . . . . . ....Previous MatchNext Match

            5. 3.5 . . . . . . . . . ....Previous MatchNext Match

            6. 3.6 . . . . . . . . . ....Previous MatchNext Match

          5. A.4. Studies of other effects Previous MatchNext Match

            1. 4.1 . . . . . . . . . ....Previous MatchNext Match

            2. 4.2 Microbiological properties of residues. Previous MatchNext Match

              1. 4.2.1 . . . . . . . . . ....Previous MatchNext Match

              2. 4.2.2 . . . . . . . . . ....Previous MatchNext Match

            3. 4.3 . . . . . . . . . ....Previous MatchNext Match

        8. B. Residue documentation Previous MatchNext Match

          1. B.0 . . . . . . . . . ....Previous MatchNext Match

          2. B.1. Precise identification of the substance concerned by the application Previous MatchNext Match

          3. B.2. Residue studies Previous MatchNext Match

            1. 2.1 Pharmacokinetics Previous MatchNext Match

            2. 2.2 . . . . . . . . . ....Previous MatchNext Match

            3. 2.3 . . . . . . . . . ....Previous MatchNext Match

          4. B3. Routine analytical method for the detection of residues Previous MatchNext Match

            1. 3.1 . . . . . . . . . ....Previous MatchNext Match

            2. 3.2 Validation of the method. Previous MatchNext Match

              1. 3.2.1 . . . . . . . . . ....Previous MatchNext Match

              2. 3.2.2 . . . . . . . . . ....Previous MatchNext Match

              3. 3.2.3 . . . . . . . . . ....Previous MatchNext Match

              4. 3.2.4 . . . . . . . . . ....Previous MatchNext Match

              5. 3.2.5 . . . . . . . . . ....Previous MatchNext Match

              6. 3.2.6 . . . . . . . . . ....Previous MatchNext Match

              7. 3.2.7 . . . . . . . . . ....Previous MatchNext Match

Yn ôl i’r brig

Options/Help

Print Options

Close

Mae deddfwriaeth ar gael mewn fersiynau gwahanol:

Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.

Gwreiddiol (Fel y’i mabwysiadwyd gan yr UE): Mae'r wreiddiol version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Close

Dewisiadau Agor

Dewisiadau gwahanol i agor deddfwriaeth er mwyn gweld rhagor o gynnwys ar y sgrin ar yr un pryd

Close

Rhagor o Adnoddau

Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:

  • y PDF print gwreiddiol y fel adopted version that was used for the EU Official Journal
  • rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
  • pob fformat o’r holl ddogfennau cysylltiedig
  • slipiau cywiro
  • dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill
Close

Llinell Amser Newidiadau

Mae’r llinell amser yma yn dangos y fersiynau gwahanol a gymerwyd o EUR-Lex yn ogystal ag unrhyw fersiynau dilynol a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig.

Cymerir dyddiadau fersiynau’r UE o ddyddiadau’r dogfennau ar EUR-Lex ac efallai na fyddant yn cyfateb â’r adeg pan ddaeth y newidiadau i rym ar gyfer y ddogfen.

Ar gyfer unrhyw fersiynau a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig, bydd y dyddiad yn cyd-fynd â’r dyddiad cynharaf y daeth y newid (e.e. ychwanegiad, diddymiad neu gyfnewidiad) a weithredwyd i rym. Am ragor o wybodaeth gweler ein canllaw i ddeddfwriaeth ddiwygiedig ar Ddeall Deddfwriaeth.

Close

Rhagor o Adnoddau

Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:

  • y PDF print gwreiddiol y fel adopted fersiwn a ddefnyddiwyd am y copi print
  • slipiau cywiro

liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys

  • rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
  • manylion rhoi grym a newid cyffredinol
  • pob fformat o’r holl ddogfennau cysylltiedig
  • dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill

The data on this page is available in the alternative data formats listed: